BELLUS Health Inc. (BLU)

NASDAQ: BLU · IEX Real-Time Price · USD
7.72
+0.11 (1.45%)
Mar 21, 2023, 4:00 PM EDT - Market closed
1.45%
Market Cap 971.12M
Revenue (ttm) 9,091
Net Income (ttm) -55.00M
Shares Out 125.79M
EPS (ttm) -0.52
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 1,346,282
Open 7.63
Previous Close 7.61
Day's Range 7.50 - 7.79
52-Week Range 5.89 - 12.69
Beta -0.51
Analysts Buy
Price Target 15.38 (+99.22%)
Earnings Date Mar 22, 2023

About BLU

BELLUS Health Inc., a clinical stage biopharmaceutical company, develops therapeutics for the treatment of refractory chronic cough (RCC) and other cough hypersensitivity indications. Its lead product candidate includes BLU-5937, an antagonist of the P2X3 receptor, which is in Phase II clinical trial for treatment of RCC and chronic pruritus. The company was incorporated in 1993 and is based in Laval, Canada. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 1993
Employees 40
Stock Exchange NASDAQ
Ticker Symbol BLU
Full Company Profile

Financial Performance

In 2021, BELLUS Health's revenue was 16,000, an increase of 6.67% compared to the previous year's 15,000. Losses were -71.22 million, 124.3% more than in 2020.

Financial numbers in CAD Financial Statements

Analyst Forecast

According to 9 analysts, the average rating for BLU stock is "Buy." The 12-month stock price forecast is $15.38, which is an increase of 99.22% from the latest price.

Price Target
$15.38
(99.22% upside)
Analyst Consensus: Buy
Stock Forecasts

News

BELLUS Health to Participate in the Cowen 43rd Annual Health Care Conference

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc.

2 weeks ago - Business Wire

Bellus Health (BLU) Reports Q3 Loss, Misses Revenue Estimates

Bellus (BLU) delivered earnings and revenue surprises of -11.11% and 60%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

4 months ago - Zacks Investment Research

BELLUS Health Reports Third Quarter 2022 Financial Results and Business Highlights

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatmen...

4 months ago - Business Wire

BELLUS Health to Participate in Two Upcoming Healthcare Investor Conferences

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatmen...

4 months ago - Business Wire

Is Bellus Health (BLU) Outperforming Other Medical Stocks This Year?

Here is how Bellus Health (BLU) and EDAP TMS S.A. (EDAP) have performed compared to their sector so far this year.

5 months ago - Zacks Investment Research

BELLUS Health to Present Clinical Data from Phase 2b SOOTHE Trial of BLU-5937 at the CHEST Annual Meeting

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment ...

5 months ago - Business Wire

BELLUS Health to Present at the H.C. Wainwright Global Investment Conference

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment ...

7 months ago - Business Wire

BELLUS Health to Present Clinical Data from Phase 2b SOOTHE Trial of BLU-5937 at the European Respiratory Society International Congress 2022

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment ...

7 months ago - Business Wire

BELLUS Health Reports Second Quarter 2022 Financial Results and Business Highlights

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment ...

7 months ago - Business Wire

BELLUS Health Closes US$153 Million Public Offering of Common Shares in Canada and the United States

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (NASDAQ: BLU)(TSX: BLU) (the “Company” or “BELLUS Health”) announced today that it has completed its previously-announced underwritten public offerin...

8 months ago - Business Wire

BELLUS Health Announces Pricing of US$153 Million Public Offering in Canada and the United States

LAVAL, Quebec--(BUSINESS WIRE)--In connection with its previously announced public offering of common shares in Canada and the United States (the “Offering”), BELLUS Health Inc. (“BELLUS Health” or th...

8 months ago - Business Wire

BELLUS Health Shares Slide On Public Offering Of Shares In Canada And US

BELLUS Health Inc (NASDAQ: BLU) (TSX:BLU) has filed a preliminary prospectus supplement to its amended and restated short form base shelf prospectus dated December 14, 2021, amending and restating the...

8 months ago - Benzinga

BELLUS Health Announces the Launch of a Public Offering of Common Shares in Canada and the United States

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (“BELLUS Health” or the “Company”) (TSX and Nasdaq: BLU), announced today the filing of a preliminary prospectus supplement (the “Supplement”) to its...

8 months ago - Business Wire

Bellus Health Announces Positive End-of-Phase 2 Meeting with the FDA and its CALM Phase 3 Program for BLU-5937 in Refractory Chronic Cough

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq: BLU; TSX: BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatmen...

9 months ago - Business Wire

Has Bellus Health (BLU) Outpaced Other Medical Stocks This Year?

Here is how Bellus Health (BLU) and Adherex Technologies Inc. (FENC) have performed compared to their sector so far this year.

9 months ago - Zacks Investment Research

BELLUS Health to Participate in the William Blair Biotech Focus Conference

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment ...

9 months ago - Business Wire

This Small-Cap Innovator is Flying High

We may be turning the page to a new chapter where small-cap stocks re-establish their supremacy.

9 months ago - Zacks Investment Research

Here's Why Bellus Health (BLU) is a Great Momentum Stock to Buy

Does Bellus Health (BLU) have what it takes to be a top stock pick for momentum investors? Let's find out.

9 months ago - Zacks Investment Research

4 Biotech Stocks With Bright Prospects to Buy Amid Recovery

New drug approvals and development of treatments for COVID-19 should maintain momentum for the Zacks Biomedical and Genetics industry. A strong portfolio and pipeline progress position ALKS, GERN, IMC...

Other symbols: ALKSGERNIMCR
10 months ago - Zacks Investment Research

Are Medical Stocks Lagging Bellus Health (BLU) This Year?

Here is how Bellus Health (BLU) and Adherex Technologies Inc. (FENC) have performed compared to their sector so far this year.

10 months ago - Zacks Investment Research

Wall Street Analysts See an 83% Upside in Bellus (BLU): Can the Stock Really Move This High?

The average of price targets set by Wall Street analysts indicates a potential upside of 83.3% in Bellus (BLU). While the effectiveness of this highly sought-after metric is questionable, the positive...

10 months ago - Zacks Investment Research

BELLUS Health to Participate in the Jefferies Healthcare Conference

LAVAL, Quebec--(BUSINESS WIRE)--BELLUS Health Inc. (Nasdaq:BLU; TSX:BLU) (“BELLUS Health” or the “Company”), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment ...

10 months ago - Business Wire

Is Bellus Health (BLU) Stock Outpacing Its Medical Peers This Year?

Here is how Bellus Health (BLU) and Adherex Technologies Inc. (FENC) have performed compared to their sector so far this year.

10 months ago - Zacks Investment Research

Wall Street Analysts Believe Bellus (BLU) Could Rally 32%: Here's is How to Trade

The average of price targets set by Wall Street analysts indicates a potential upside of 31.6% in Bellus (BLU). While the effectiveness of this highly sought-after metric is questionable, the positive...

11 months ago - Zacks Investment Research